open access

Vol 20, No 6 (2013)
Original articles
Published online: 2013-12-11
Get Citation

Effects of age on aerobic capacity in heart failure patients under beta-blocker therapy: Possible impact in clinical decision-making?

Emmanuel Gomes Ciolac, Edimar Alcides Bocchi, Miguel Morita Fernandes da Silva, Aline Cristina Tavares, Iram Soares Teixeira-Neto, Guilherme Veiga Guimarães
DOI: 10.5603/CJ.2013.0166
·
Cardiol J 2013;20(6):655-661.

open access

Vol 20, No 6 (2013)
Original articles
Published online: 2013-12-11

Abstract

Background: Heart failure (HF) is associated with impaired maximal aerobic capacity asindicated by decreases in peak oxygen uptake (peak VO2). Considering that aging by itself has a negative effect on this variable, the evaluation of maximum capacity is often questioned because current predicted peak VO2 is based on subjects without heart disease or b-blocker therapy. In contrast, if decline in predicted and attained peak VO2 were age-related, proportionally, loss ofaerobic function (predicted peak VO2, %) would remain stable over time in these patients. The purpose of this investigation is to assess the effects of age on peak VO2 in HF patients taking b-blockers.\

Methods: We retrospectively evaluated 483 (132 female) patients (aged 20–88 years, LVEF31 ± 11%) with non-ischemic (n = 362), ischemic (n = 74) and Chagas-related HF (n = 47) who had been submitted to an incremental cardiopulmonary exercise testing on a motorized treadmill. Linear regression was used to develop the equation to predict peak VO2, based on age.

Results: Peak VO2 decreased 0.9 mL/min/kg per age-decade, maximum HR also decreased with aging and VE/VCO2 slope was similar among all decades. The predicted new b-blocker equation to peak VO2 bb was 20.934 – 0.092 × age.

Conclusions: Clinical interpretation of aerobic capacity impairment is infl uenced by agingin HF patients. This evidence must be considered when using peak VO2 for prognostic stratification and clinical decision-making in patients with HF under b-blocker therapy.

Abstract

Background: Heart failure (HF) is associated with impaired maximal aerobic capacity asindicated by decreases in peak oxygen uptake (peak VO2). Considering that aging by itself has a negative effect on this variable, the evaluation of maximum capacity is often questioned because current predicted peak VO2 is based on subjects without heart disease or b-blocker therapy. In contrast, if decline in predicted and attained peak VO2 were age-related, proportionally, loss ofaerobic function (predicted peak VO2, %) would remain stable over time in these patients. The purpose of this investigation is to assess the effects of age on peak VO2 in HF patients taking b-blockers.\

Methods: We retrospectively evaluated 483 (132 female) patients (aged 20–88 years, LVEF31 ± 11%) with non-ischemic (n = 362), ischemic (n = 74) and Chagas-related HF (n = 47) who had been submitted to an incremental cardiopulmonary exercise testing on a motorized treadmill. Linear regression was used to develop the equation to predict peak VO2, based on age.

Results: Peak VO2 decreased 0.9 mL/min/kg per age-decade, maximum HR also decreased with aging and VE/VCO2 slope was similar among all decades. The predicted new b-blocker equation to peak VO2 bb was 20.934 – 0.092 × age.

Conclusions: Clinical interpretation of aerobic capacity impairment is infl uenced by agingin HF patients. This evidence must be considered when using peak VO2 for prognostic stratification and clinical decision-making in patients with HF under b-blocker therapy.

Get Citation

Keywords

aging, b-blocker therapy, cardiopulmonary exercise test, cardiorespiratory fitness, heart failure

About this article
Title

Effects of age on aerobic capacity in heart failure patients under beta-blocker therapy: Possible impact in clinical decision-making?

Journal

Cardiology Journal

Issue

Vol 20, No 6 (2013)

Pages

655-661

Published online

2013-12-11

DOI

10.5603/CJ.2013.0166

Bibliographic record

Cardiol J 2013;20(6):655-661.

Keywords

aging
b-blocker therapy
cardiopulmonary exercise test
cardiorespiratory fitness
heart failure

Authors

Emmanuel Gomes Ciolac
Edimar Alcides Bocchi
Miguel Morita Fernandes da Silva
Aline Cristina Tavares
Iram Soares Teixeira-Neto
Guilherme Veiga Guimarães

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl